Relja Maja, Klepac Natasa
Department of Neurology, Medical School, University of Zagreb, Kispatićeva 12, HR-10000 Zagreb, Croatia.
J Neurol Sci. 2006 Oct 25;248(1-2):251-4. doi: 10.1016/j.jns.2006.05.027. Epub 2006 Jun 22.
The cognitive performance of 55 non-demented idiopathic Parkinson's disease (PD) patients treated with levodopa alone or receiving dopamine agonist pramipexole as add-on therapy to levodopa was evaluated in the present study during 6 months of treatment. Neuropsychological tests were administered two times. In the first assessment to differentiate test sensitive to cognitive changes typical for PD control group was also assessed. After 6 months of treatment PD patients were retested only with tests that differentiate them from control group. Compared to controls PD patients showed inferior performance on Stroop Interference test, Trail Making test, letter fluency and Hooper Visual Organization Test. No statistically significant differences between two groups and first and second neuropsychological assessment were found. Present findings indicate that pramipexole as add-on therapy to levodopa is safe in non-demented PD patients in terms of the effect on cognitive performance.
在本研究中，对55例仅接受左旋多巴治疗或接受多巴胺激动剂普拉克索作为左旋多巴附加疗法的非痴呆型特发性帕金森病（PD）患者在6个月的治疗期间的认知表现进行了评估。神经心理学测试进行了两次。在第一次评估中，为了区分对PD典型认知变化敏感的测试，还评估了对照组。治疗6个月后，仅用能将PD患者与对照组区分开的测试对PD患者进行重新测试。与对照组相比，PD患者在斯特鲁普干扰测试、连线测验、字母流畅性和胡珀视觉组织测试中的表现较差。两组之间以及第一次和第二次神经心理学评估之间未发现统计学上的显著差异。目前的研究结果表明，就对认知表现的影响而言，普拉克索作为左旋多巴的附加疗法在非痴呆型PD患者中是安全的。
